01.07.2024 15:10:38

Vera Therapeutics Appoints David Johnson As COO

(RTTNews) - Vera Therapeutics, Inc. (VERA), a company focused on patients with serious immunological diseases, said on Monday that it has appointed David Johnson as Chief Operating Officer, effective immediately.

Johnson brings more than 30 years of commercialization and operational experience in the biopharmaceutical industry.

Johnson joins Vera from Global Blood Therapeutics, where he served as the Chief Commercial Officer until it was acquired by Pfizer in 2022.

Prior to that, Johnson spent 15 years at Gilead Sciences in roles of increasing responsibility, most recently as Vice President of Sales and Marketing for Gilead's Liver Disease Business Unit.

Johnson previously had an 11-year tenure at GSK plc.

Nachrichten zu Vera Therapeutics Inc Registered Shs -A-mehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Vera Therapeutics Inc Registered Shs -A-mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Vera Therapeutics Inc Registered Shs -A- 37,02 -12,25% Vera Therapeutics Inc Registered Shs -A-